UA129265C2 - Лікування головного болю при надмірному застосуванні лікарських препаратів антитілами до cgrp або cgrp-r - Google Patents

Лікування головного болю при надмірному застосуванні лікарських препаратів антитілами до cgrp або cgrp-r Download PDF

Info

Publication number
UA129265C2
UA129265C2 UAA202104194A UAA202104194A UA129265C2 UA 129265 C2 UA129265 C2 UA 129265C2 UA A202104194 A UAA202104194 A UA A202104194A UA A202104194 A UAA202104194 A UA A202104194A UA 129265 C2 UA129265 C2 UA 129265C2
Authority
UA
Ukraine
Prior art keywords
antibody
socrp
socr
headache
antibody fragment
Prior art date
Application number
UAA202104194A
Other languages
English (en)
Ukrainian (uk)
Inventor
Роджер Кей. Кеді
Роджер Кэй. Кэди
Джеффрі Ті.Л. Сміт
Джеффри Ти.Л. Смит
Джозеф Гірман
Джозеф Хирман
Барбара Шеффлер
Лахар Мехта
Original Assignee
Х. Луннбек А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Луннбек А/С filed Critical Х. Луннбек А/С
Publication of UA129265C2 publication Critical patent/UA129265C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
UAA202104194A 2019-01-08 2020-01-08 Лікування головного болю при надмірному застосуванні лікарських препаратів антитілами до cgrp або cgrp-r UA129265C2 (uk)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962789828P 2019-01-08 2019-01-08
US201962840967P 2019-04-30 2019-04-30
US201962841585P 2019-05-01 2019-05-01
US201962872983P 2019-07-11 2019-07-11
PCT/US2020/012790 WO2020146535A1 (en) 2019-01-08 2020-01-08 Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies

Publications (1)

Publication Number Publication Date
UA129265C2 true UA129265C2 (uk) 2025-03-05

Family

ID=71404208

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202104194A UA129265C2 (uk) 2019-01-08 2020-01-08 Лікування головного болю при надмірному застосуванні лікарських препаратів антитілами до cgrp або cgrp-r

Country Status (24)

Country Link
US (2) US20200216525A1 (https=)
EP (1) EP3908607A4 (https=)
JP (2) JP2022516957A (https=)
KR (1) KR20210114002A (https=)
CN (2) CN119303074A (https=)
AU (1) AU2020207299A1 (https=)
BR (1) BR112020018044A2 (https=)
CA (1) CA3123292A1 (https=)
CL (1) CL2021001813A1 (https=)
CO (1) CO2021008665A2 (https=)
DO (1) DOP2021000145A (https=)
EC (1) ECSP21052193A (https=)
GE (2) GEP20257804B (https=)
IL (1) IL284677A (https=)
JO (1) JOP20210166A1 (https=)
MA (1) MA54709A (https=)
MX (1) MX2021008268A (https=)
NI (1) NI202100063A (https=)
PE (1) PE20211708A1 (https=)
PH (1) PH12021551494A1 (https=)
SG (1) SG11202106878XA (https=)
TW (1) TW202030205A (https=)
UA (1) UA129265C2 (https=)
WO (1) WO2020146535A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
TWI685505B (zh) 2011-05-20 2020-02-21 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
NZ717704A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
CN113227140A (zh) 2019-01-08 2021-08-06 H.隆德贝克有限公司 使用抗cgrp抗体急性治疗和快速治疗头痛
KR20210124867A (ko) 2020-04-06 2021-10-15 하. 룬드벡 아크티에셀스카브 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료
EP4392447A1 (en) * 2021-08-27 2024-07-03 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies
WO2024032750A1 (zh) * 2022-08-11 2024-02-15 上海君实生物医药科技股份有限公司 抗cgrp抗体及用途
CN118476508A (zh) * 2024-06-27 2024-08-13 中国人民解放军总医院第一医学中心 一种基于疾病发生特点的药物过度使用性头痛动物模型的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
AU2012258980B8 (en) * 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
TWI685505B (zh) * 2011-05-20 2020-02-21 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
CN103585449B (zh) * 2013-10-23 2016-06-22 高丽丽 用于治疗偏头痛的中药组合物
CA2982861A1 (en) * 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
WO2017186928A1 (en) * 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
WO2018055574A1 (en) * 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
CN113227140A (zh) * 2019-01-08 2021-08-06 H.隆德贝克有限公司 使用抗cgrp抗体急性治疗和快速治疗头痛

Also Published As

Publication number Publication date
BR112020018044A2 (pt) 2021-08-10
CN113272324A (zh) 2021-08-17
JP2025032102A (ja) 2025-03-11
MA54709A (fr) 2022-04-13
GEP20257804B (en) 2025-10-10
SG11202106878XA (en) 2021-07-29
MX2021008268A (es) 2021-08-05
CA3123292A1 (en) 2020-07-16
PH12021551494A1 (en) 2023-05-08
EP3908607A4 (en) 2022-10-05
PE20211708A1 (es) 2021-09-01
DOP2021000145A (es) 2021-10-31
US20240343784A1 (en) 2024-10-17
AU2020207299A1 (en) 2021-08-26
TW202030205A (zh) 2020-08-16
EP3908607A1 (en) 2021-11-17
KR20210114002A (ko) 2021-09-17
US20200216525A1 (en) 2020-07-09
CN119303074A (zh) 2025-01-14
CO2021008665A2 (es) 2021-07-19
GEAP202515689A (en) 2025-04-25
IL284677A (en) 2021-08-31
JP2022516957A (ja) 2022-03-03
CL2021001813A1 (es) 2021-12-24
NI202100063A (es) 2021-12-01
WO2020146535A1 (en) 2020-07-16
ECSP21052193A (es) 2021-08-31
JOP20210166A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
UA129265C2 (uk) Лікування головного болю при надмірному застосуванні лікарських препаратів антитілами до cgrp або cgrp-r
TWI839435B (zh) 使用抗cgrp 抗體急性治療和快速治療頭痛
CN1518458B (zh) 移植物排斥反应抑制剂
CA2955254A1 (en) Identification of cancer genes by in-vivo fusion of human cancer cells and animal cells
US20260102505A1 (en) Anti-cd45-ign antibody drug conjugates and uses thereof
CA3107119A1 (en) Use of interleukin-7 and chimeric antigen receptor (car)-bearing immune effector cells for treating tumor
JP2026016471A (ja) 抗ｃｇｒｐ抗体を用いた頭痛の治療
CA3102372A1 (en) Methods of use of cd24 for the prevention and treatment of graft versus host disease and mucositis
JP7749495B2 (ja) 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン
JP7748311B2 (ja) 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン
RU2826186C2 (ru) Лечение головной боли при избыточном применении лекарственных препаратов антителами к cgrp или cgrp-r
JP2024532143A (ja) 抗ｃｇｒｐ抗体を使用した群発頭痛の治療